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Abstract
177Lu-octreotate is an FDA-approved radionuclide therapy for patients with 
gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin 
receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by 
prolonging progression-free survival, but complete responses are still uncommon. The 
aim of this study was to improve the 177Lu-octreotate therapy by means of combination 
therapy. To identify radiosensitising inhibitors, two cell lines, GOT1 and P-STS, derived 
from small intestinal neuroendocrine tumours (SINETs), were screened with 1224 
inhibitors alone or in combination with external radiation. The screening revealed 
that inhibitors of Hsp90 can potentiate the tumour cell-killing effect of radiation in a 
synergistic fashion (GOT1; false discovery rate <3.2 × 10−11). The potential for Hsp90 
inhibitor ganetespib to enhance the anti-tumour effect of 177Lu-octreotate in an in vivo 
setting was studied in the somatostatin receptor-expressing GOT1 xenograft model. 
The combination led to a larger decrease in tumour volume relative to monotherapies 
and the tumour-reducing effect was shown to be synergistic. Using patient-derived 
tumour cells from eight metastatic SINETs, we could show that ganetespib enhanced the 
effect of 177Lu-octreotate therapy for all investigated patient tumours. Levels of Hsp90 
protein expression were evaluated in 767 SINETs from 379 patients. We found that 
Hsp90 expression was upregulated in tumour cells relative to tumour stroma in the vast 
majority of SINETs. We conclude that Hsp90 inhibitors enhance the tumour-killing effect 
of 177Lu-octreotate therapy synergistically in SINET tumour models and suggest that this 
potentially promising combination should be further evaluated. Endocrine-Related Cancer  
(2019) 26, 437–449
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Introduction
The 177Lu-[DOTA0,  Tyr3]-octreotate therapy, or 
177Lu-octreotate therapy, is targeted against well-
differentiated neuroendocrine tumours expressing 
somatostatin receptors. Following a promising retrospective 
study (Kwekkeboom et al. 2008, Brabander et al. 2017), it 
was recently shown in a phase 3 trial that 177Lu-octreotate 
markedly increased progression-free survival (65.2% 
vs 10.8% after 20  months) and significantly improved 
response rates (18% vs 3% after 20 months) in patients 
with small intestinal neuroendocrine tumours (SINETs), 
compared with the best standard of care (Strosberg et al. 
2017). This has led to an FDA approval of 177Lu-octreotate 
therapy for gastroenteropancreatic NETs and its inclusion 
in treatment guidelines (Hicks et  al. 2017). However, 
although response rates were improved, partial and 
complete responses (17% and 1% respectively) after 
177Lu-octreotate therapy were still limited, emphasising 
the need to further optimise 177Lu-octreotate therapy. 
It has been shown in a human SINET xenograft model 
that administration of 177Lu-octreotate at high enough 
doses may result in complete tumour remission (Kölby 
et al. 2005). Increasing the dose may also have beneficial 
effects in the clinical setting, but could also give increased 
adverse effects. The most commonly reported severe 
adverse effects from 177Lu-octreotate therapy include 
renal failure, haematological toxicity and gastrointestinal 
disorders (Bergsma et  al. 2016, Brabander et  al. 2017, 
2018). An alternative to increasing the treatment dose 
would be to use a combination therapy which improves 
the beneficial effect of 177Lu-octreotate without increasing 
the adverse effects (Fitzgerald et  al. 2006). Attempts to 
combine 177Lu-octreotate with compounds that can 
enhance the therapeutic efficacy have been performed 
in preclinical studies (Elf et  al. 2017, Spetz et  al. 2017) 
and clinical studies (Claringbold & Turner 2015, 2016, 
Kashyap et  al. 2015), with varying effect and without 
reported synergistic effects. Large-scale screening for 
candidate inhibitors that can enhance 177Lu-octreotate 
therapy and that could be used for combination therapy 
has not yet been performed.
In the present study, we performed a synergy 
screening to identify inhibitors that could enhance 
177Lu-octreotate therapy. We found that the heat shock 
protein inhibitor ganetespib enhanced the tumour-
killing efficacy of 177Lu-octreotate therapy in a synergistic 
manner, as demonstrated in SINET models in vitro, in vivo 
and ex vivo.
Materials and methods
Cell lines and patient-derived tumour cells
The GOT1 cell line was established from a liver metastasis 
of a midgut carcinoid (Kölby et al. 2001) and was cultured 
in RPMI1640 supplemented with 10% foetal bovine 
serum (FBS), 5 μg/mL insulin and 5 μg/mL transferrin. The 
P-STS cell line was a gift from Professor R Pfragner. It was 
established from the primary tumour, described as a grade 
3 NET located in the terminal ileum (Pfragner et al. 2009), 
and was cultured in M199:Ham’s F12 (1:1) supplemented 
with 10% FBS. The cell lines were regularly tested for 
Mycoplasma species as described by van Kuppeveld et al. 
(van Kuppeveld et al. 1994) at a Swedac SS-EN ISO 15189 
accredited laboratory (Sahlgrenska University Hospital, 
Gothenburg, Sweden). The identity of the cell lines was 
validated by STR analysis (Hofving et al. 2018).
Patient-derived tumour cells were established from 
biopsies of metastatic SINETs collected at the time of 
surgery, and prepared as previously described (Arvidsson 
et  al. 2010). Clinical and histopathological data on 
patients and tumours are given in Table 1. The purity of 
primary cell cultures was assessed by light microscopy 
using haematoxylin and eosin-stained sections from cell 
blocks and was shown to be ≥95%. All patient-derived 
tumour cells were treated 24 h after establishment and 
kept in RPMI1640 supplemented with 4% FBS during 
experiments. The medium of all cell lines and patient-
derived tumour cells also contained 100 IU/mL penicillin 
and 100 μg/mL streptomycin.
Pharmaceuticals and external radiation
The screening library consisted of 1224 inhibitors (L1100, 
Selleckchem). The library was batched in 96-well plates 
and stored at −80°C. The plates were subjected to no more 
than five freeze-thaw cycles. For in vitro experiments, 
ganetespib (Selleckchem) was aliquoted in DMSO and 
for in vivo experiments prepared in 5% DMSO and 45% 
PEG in ddH2O by applying a low amount of heat until 
dissolved, and was stored at −20°C.
Radiolabelling of [DOTA0,  Tyr3]-octreotate with 
177Lu and subsequent thin-layer chromatography 
quality control was performed as previously described 
(Dalmo et  al. 2017). The proportion of peptide-bound 
177Lu was >99%. Each syringe was measured before and 
after administration of the radiopharmaceutical with a 
well-type ionisation chamber (CRC-15R, Capintec).
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External radiation was given using a Varian TrueBeam 
linear accelerator with 6-MV nominal photon energy 
and a dose rate of 8.2 Gy/min absorbed dose to water. 
During irradiation, cell culture plates were held in a 
220 × 220 × 90 mm3 polystyrene phantom. The height of 
the media in each well was 2 mm and the thickness of 
the cell layer was approximately 20 µm. The cell layer was 
positioned at a height corresponding to the distance for 
the dose maximum of the radiation beam. Irradiation was 
given at a 180° gantry angle (upwards irradiation), the 
source surface distance was 900 mm. The radiation field at 
the isocenter (1000 mm) was 200 × 200 mm2.
In vitro cell experiments
For all experiments, 50,000 cells were seeded onto 
black non-optical 96-well cell culture plates (Nunc, 
Thermo Fisher Scientific) and 24 h was allowed for cell 
attachment before the start of the experiment. At the end 
of all experiments, the cell viability was estimated using 
alamarBlue (Thermo Fisher Scientific), a fluorescence-
based assay for measurement of the reducing capacity of 
metabolically active cells. All assay plates were incubated 
for 6 h at 37°C, and were then analysed with a fluorescence 
plate reader (Wallac 1420, PerkinElmer; ex. 560 nm and 
em. 640 nm).
For screening experiment, the inhibitor library 
was added to 96-well culture plates, with each plate 
also including internal DMSO controls (N = 8). In 
addition, each experiment included one cell-free plate 
for background subtraction (N = 96) and one DMSO-
treated plate as vehicle control (N = 96). The screening 
library was added to a final concentration of 1 µM. After 
adding the inhibitor library, combination-treated cells 
were subjected to 3 Gy external radiation within 30 min. 
Experiments were repeated two or three times for 
inhibitors only, for radiation only and for combination 
treatment. Screening experiments were ended after 48 h. 
For cell line dose-response experiments with ganetespib, 
GOT1 and P-STS were treated with ganetespib at indicated 
doses for 72 h before plates were analysed. Each dose 
included four replicates and the experiment repeated 
three times. For experiment with patient-derived tumour 
cells, first-passage cell cultures were generated from eight 
patients. The cells were treated with radiation (0 Gy, 
7.5 Gy, or 10 Gy), ganetespib (0, 0.1, 1, or 10 µM) or 
both treatments combined (all dose combinations). For 
each patient and treatment the experiment included 12 
replicates and was performed once due to the limited cell 
numbers. Cell plates were analysed 72 h after the start of 
the experiment.
Tumour xenograft model and animal handling
GOT1 tissue was transplanted subcutaneously to BALB/c 
nude mice (Janvier Labs, Le Genest-Saint-Isle, France) 
as previously described (Kölby et  al. 2001, Dalmo et  al. 
2017). The tumour response was evaluated in mice 
treated with a single intravenous tail vein injection of 
vehicle (N = 6), 15 MBq 177Lu-octreotate (N = 5), 50 mg/kg 
ganetespib (N = 5) or a combination of both treatments 
(N = 5). These amounts, and the single-administration 
design, were chosen in order to obtain a moderate but 
clearly measurable treatment effect of each monotherapy. 
Mouse tumours were measured twice weekly with slide 
callipers. Growth inhibition was calculated as the relative 
tumour volume compared to vehicle-treated mice at a 
given time point. Tumour regression was calculated as 
the relative tumour volume compared to treatment start. 
Water and autoclaved food were available ad libitum. After 
14  days the experiment was ended and mice sacrificed 
by intraperitoneal injection of 60 mg/mL pentobarbital 
Table 1 Clinicopathological characteristics of patients with small intestinal neuroendocrine tumours used to evaluate 
177Lu-octreotate synergy.
Patient #
Age at 
surgery Gender Tumour sitea
 
Grade (WHO 2010)a KI67 (%)a
Stage  
(TNM 7th edn)
 
SSTR2 score (0–3)
 
HSP90 score (high/low)
1 81 M LN G1 0.3 IV 2 High
2 76 M LN G1 0.6 III 3 High
3 59 F LN G1 1.1 IV 2 High
4 68 M LN G2 3.3 III 3 Low
5 40 M L G1 0.3 IV 3 Low
6 61 M L G1 0.4 IV 2 High
7 67 M L G2 2.3 IV 2 High
8 71 F L G2 2.4 IV 3 High
aData for the specific tumour from which primary cells were derived.
F, female; L, liver metastasis; LN, lymph node metastasis; M, male.
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(Pentobarbitalnatrium vet., Apotek Produktion & 
Laboratorier), followed by cardiac puncture.
Chromogranin A assay
When mice were sacrificed at the end point of 
the experiment, plasma was collected and human 
chromogranin A was quantified using ELISA according to 
the manufacturer’s instructions (ab196271, Abcam). All 
samples and chromogranin A standards were analysed 
using two technical replicates.
Tissue microarray
The tissue microarray was generated from patients who 
underwent surgery for SINETs at Sahlgrenska University 
Hospital in the years 1986 to 2013. Details of the 
construction of the tissue microarray have been described 
previously (Arvidsson et al. 2018).
Immunohistochemistry
Immunohistochemistry was performed on xenografted 
tumours, patient-derived tumour cells, patient tumour 
tissue and tissue microarrays. Tumours xenografted to 
mice were immediately excised after the mouse was 
sacrificed, and fixed in 4% buffered formaldehyde and 
then embedded in paraffin. Patient-derived tumour cells 
were fixed in methanol. Cell blocks from patient-derived 
tumour cells were created using a Cellient automated 
cell block system (Hologic). Tissue blocks from patient 
tumours were obtained from Sahlgrenska University 
Hospital. These blocks were prepared for routine clinical 
histopathology. Tissue microarrays were generated as 
described above.
Sections (3–4 μm) from paraffin blocks were placed on 
glass slides and treated in Dako PT-Link using EnVision 
FLEX Target Retrieval Solution (high pH). The following 
primary antibodies were used: anti-chromogranin A (PHE5, 
Chemicon and EP1030Y, Abcam), anti-synaptophysin 
(DAK-SYNAP, Dako and SP11, Abcam), anti-5HT (H209, 
Dako and LS-B7118, LSBio), anti-pan-cytokeratin (AE1/AE3, 
Dako), anti-SSTR2A (UMB-1, Abcam), anti-Ki67 
(MIB-1, Dako) and anti-Hsp90 (EPR3953, Abcam). 
Immunohistochemical staining was performed in a 
Dako Autostainer Link using EnVision FLEX according 
to the manufacturer’s instructions (DakoCytomation). 
EnVision FLEX+ (LINKER) rabbit or mouse was used for 
all stainings except anti-chromogranin A (PHE5) and 
anti-pan-cytokeratin. Positive and negative controls were 
included in each run. Tumour regression was evaluated by 
board-certified pathologist (O.N.) and scored according to 
Becker et al. (2003) into four categories: ‘1a’ (no tumour), 
‘1b’ (<10% remaining tumour), ‘2’ (10−50% remaining 
tumour) and ‘3’ (>50% remaining tumour). Scoring of 
Hsp90 expression in tumour cells vs stroma was evaluated 
in 701 SINETs from 369 patients and was based on the 
staining intensity of tumour cells relative to surrounding 
stromal cells and was categorised as lower, equal or higher. 
The overall Hsp90 expression was evaluated in 767 SINETs 
from 379 patients and based on the staining intensity 
of tumour cells scored as ‘1’ or ‘2’. The Ki67 index was 
calculated by manually counting the percentage of 
labelled tumour cell nuclei on printed images (Reid et al. 
2015).
Ethics approval
We obtained approval from Regional Ethical Review 
Boards in Gothenburg, Sweden, for the use of clinical 
materials for research purposes and for all animal 
procedures. Consent has been obtained from each patient 
after full explanation of the purpose and nature of all 
procedures used.
Data analysis
For each cell line, inhibitor fluorescence intensities 
generated by the cell viability assay were log-transformed 
and normalised to a common scale. For each inhibitor, 
the interaction between radiation and inhibition was 
analysed using a two-way ANOVA with an interaction 
term. Significance was calculated based on the size of the 
interaction term. The false discovery rates (FDRs) were 
calculated using the Benjamini–Hochberg algorithm 
(Benjamini & Hochberg 1995). Overrepresentation of 
inhibitor classes among significant and non-significant 
inhibitors (P < 0.05) was assessed using Fisher’s exact test. 
The FDRs for the overrepresented inhibitor classes were 
calculated as above. The analysis of the longitudinal 
in vivo experiment was done based on the log-transformed 
relative tumour size of xenografted tumours. A linear 
mixed model was fitted to tumour volume measurements 
for each treatment (vehicle, external radiation, Hsp90 
inhibition and combination treatment) with a random 
slope parameter modelling the growth rate. Synergy 
between treatments was assessed by comparing the 
effect size (slope) of the combined treatment with the 
sum of the effect sizes from the individual treatments. 
Significance was calculated using a Z-test with effect sizes 
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and standard errors estimated by the linear mixed models. 
Any P value less than 0.05 was considered statistically 
significant. Comparisons of regression score (Becker score) 
between treatment groups was done using the Mann–
Whitney nonparametric test. The analysis of the cell 
viability data from the experiments with patient-derived 
tumour cells was done as follows. Technical replicates 
were averaged and relative intensities, in comparison to 
the control, were calculated. For each radiation level (0, 
7.5 and 10 Gy), a linear model was used to estimate the 
trend in relation to the log-transformed concentration of 
ganetespib. The difference in slope between radiation and 
vehicle control was used to assess synergy. Any P value 
less than 0.05 was considered statistically significant. 
Survival analysis, testing the difference in overall survival 
from time of surgery between high and low expression of 
Hsp90 was performed using Kaplan–Meier estimator with 
log-rank test. For patients with multiple tumours (more 
than one tumour site) only one tumour was included 
with the following priority: primary tumour, lymph 
node metastasis and hepatic metastasis. The survival 
analysis using the full patient cohort consisted of 
312 patients and the 177Lu-octreotate-treated cohort 
consisted of 43 patients.
Results
Inhibitors of heat shock protein 90 synergised with 
ionising radiation to kill neuroendocrine tumour cells
In an attempt to identify inhibitors that might increase 
the potency of 177Lu-octreotate therapy in a synergistic 
manner, we screened cell lines GOT1 and P-STS using 
an inhibitor library consisting of 1224 inhibitors, both 
as single agents and in combination with external 
radiation. We were able to identify 28 and 37 inhibitors, 
respectively, in screenings of GOT1 and P-STS cells that 
significantly synergised with radiation (P < 0.05) in killing 
tumour cells in vitro (Supplementary Table 1, see section 
on supplementary data given at the end of this article). 
I-BET151, a BET bromodomain inhibitor (Dawson et  al. 
2011), showed significant synergistic effects in both cell 
lines. Using a group analysis of inhibitor classes, Hsp90 
inhibitors were found to be strongly overrepresented 
among significant synergistic inhibitors in the GOT1 
cell line (FDR = 3.2 × 10−11), with 11 out of 18 inhibitors 
having a significant synergistic effect (Fig. 1A). None of 
the Hspi showed however synergistic effects in the P-STS 
cell line (0/18). Apart from Hsp90i, no other inhibitor 
class was significantly overrepresented (FDR <0.05) 
among synergistic inhibitors in either cell line. P-STS 
was more sensitive to external radiation compared to 
GOT1 at IC50 (IC50 = 7.2 Gy vs not reached) and GOT1 
was more sensitive to ganetespib compared to P-STS 
at all tested concentrations (Fig.  1B). The expression of 
Hsp90α/β protein in both cell lines was confirmed by 
immunohistochemical staining (Fig. 1C).
177Lu-octreotate therapy was enhanced by heat shock 
protein inhibition in the GOT1 xenograft
First-generation Hsp90 inhibitors have been shown 
to sensitise cancer cells to radiation (Dote et  al. 2006, 
Lauber et  al. 2015, Wang et  al. 2016). In our screening 
experiments, we observed that Hsp90i synergised with 
external radiation in the SINET-derived cell line GOT1. 
We hypothesised that ganetespib, an Hsp90 inhibitor 
with a manageable side effect profile (Socinski et al. 2013), 
would also enhance the radionuclide 177Lu-octreotate 
therapy. To study this effect in vivo, we used the GOT1 
xenograft model, which is advantageous for studies 
of peptide receptor radiotherapy due to its expression 
of somatostatin receptor subtype 2 (SSTR2) (Kölby 
et  al. 2005, Swärd et  al. 2008, Hofving et  al. 2018). The 
tumour response was evaluated in mice treated with 
single intravenous injections of vehicle, 177Lu-octreotate, 
ganetespib or a combination of both treatments.
The tumour volume of all mouse tumours were 
measured twice weekly and the experiment was ended 
after 14 days (Fig. 2A and Supplementary Fig. 1). Under the 
experimental conditions chosen for the monotherapies, 
ganetespib alone did not lead to tumour regression but 
led to 16% tumour growth inhibition relative to vehicle-
treated tumours at the end point of the experiment. 
177Lu-octreotate led to 7% tumour regression compared 
with treatment start at the time of maximum response 
(10 days). The combination therapy had the overall best 
response, leading to 42% tumour regression compared 
with treatment start after 10 days. To determine whether 
there was synergy between ganetespib and 177Lu-octreotate 
in reducing tumour volume, we performed a longitudinal 
analysis using a linear mixed-model analysis applied 
over time points with sustained treatment effect (0 to 
10  days, Fig.  2B). The analysis indicated that the two 
treatments synergised in reducing tumour volume, but 
this was only significant (P = 0.016) after excluding one 
extreme individual in the ganetespib monotherapy group 
with a value >3.5 standard deviations from the mean 
(otherwise P = 0.13). The extreme individual belonged to 
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the ganetespib-treated group and had a tumour which 
regressed 48% after 14 days. The other ganetespib-treated 
mice had tumours that instead progressed, with an 
average tumour growth of 55%.
We also measured chromogranin A in plasma, a 
biomarker used to monitor SINETs (Arnold et  al. 2008, 
Yao et  al. 2011), at the end of experiment. Human 
chromogranin A could be detected in the plasma of 
all mice with xenografted GOT1 tumours. There was, 
however, no correlation between chromogranin A levels 
and tumour volume or treatment modality. We also 
quantified tumour regression according to Becker (Becker 
et  al. 2003) and compared the amount of remaining 
tumour tissue between vehicle-treated tumours and the 
other treatment groups (Supplementary Fig. 2). All vehicle-
treated tumours had more than 50% tumour remaining 
(score 3). In the other treatment groups the majority of 
the tumours also scored 3, but in addition contained one 
or two tumours with 10–50% remaining tumour (score 2). 
The difference between vehicle-treated tumours and 
the other treatment groups or between vehicle-treated 
tumours and all other treatment groups together was not 
statistically significant. Morphological analysis of tumour 
xenografts showed neuroendocrine differentiation with 
strong immunohistochemical staining for synaptophysin, 
chromogranin A, serotonin and pan-cytokeratin (Fig. 2C). 
All xenografted tumours were strongly stained for SSTR2 
and Hsp90α/β.
The anti-tumour effect of external radiation on 
patient-derived tumour cells was enhanced 
by ganetespib
To investigate whether the radiosensitisation that was 
induced by Hsp90 inhibition might apply to SINETs in 
general or to a specific subgroup, we investigated the 
effect of external radiation combined with ganetespib 
on first-passage patient-derived tumour cells that were 
Figure 1
Effect of Hsp90 inhibition in combination with external radiation on GOT1 and P-STS. GOT1 and P-STS cells were treated with 1224 inhibitors alone and in 
combination with external radiation. (A) Hsp90 inhibitors (red dots) were overrepresented among inhibitors that significantly synergised with external 
radiation to decrease the viability of GOT1 cells, but not P-STS cells. (B) Dose-response curves of external radiation and ganetespib on the viability of the 
GOT1 and P-STS cell lines. Dots represent mean and error bars show standard deviation. (C) Immunohistochemical staining of SINET-derived cell lines 
confirmed the expression of Hsp90α/β.
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isolated from patient metastatic tumours collected at 
surgery. Tumours from eight patients with varying clinical 
characteristics were used (Table  1). The diagnosis of all 
patient tumours was re-evaluated and confirmed to be 
well-differentiated neuroendocrine tumours of grade 1 or 
2. All patient tumours were positive for chromogranin A, 
synaptophysin, serotonin, SSTR2 and Hsp90.
First-passage single-cell suspensions were generated 
from patient tumours, seeded onto plates and treated 
after adhering. To verify the authenticity of the cultures 
generated, cell blocks were prepared and stained for 
synaptophysin, chromogranin A, serotonin, pan-
cytokeratin, SSTR2 and Hsp90. All the protein markers 
investigated were strongly expressed.
Tumour cells were treated with ganetespib, external 
radiation or a combination of both at all dose combinations 
(Fig.  3A). Cells treated with the combination showed 
much lower viability compared to the monotherapies. 
When we performed an analysis of synergy by fitting a 
linear trend line for the cell viability as a function of the 
concentration of ganetespib, we could see the viability of 
radiation-treated cells decrease more quickly, confirming 
that there was a synergistic interaction (7.5 Gy: P = 0.026; 
10 Gy: P = 0.014) (Supplementary Fig.  3). For all eight 
individual patient tumours, there was a consistent trend 
towards synergy (Fig. 3B).
Hsp90 was overexpressed in neuroendocrine tumours
In response to proteotoxic stressors, expression of heat 
shock proteins is upregulated to enable cell survival. 
Such stressors are usually prevalent in cancer cells, 
and Hsp90 inhibition has thus been proposed as a 
therapeutic opportunity with malignant tumours 
(Whitesell & Lindquist 2005). The expression of Hsp90 
in SINETs has not been reported previously. We therefore 
examined the expression of Hsp90 in a cohort of 767 
SINETs from 379 patients with immunohistochemistry. 
Figure 2
Hsp90 inhibition improves the tumour-killing effect of 177Lu-octreotate in the GOT1 xenograft model in a synergistic manner. (A) The combination therapy 
of Hsp90i ganetespib and 177Lu-octreotate had a higher tumour-killing effect than monotherapy. One extreme individual (with a value >3.5 standard 
deviations (s.d.) from the mean) was excluded from the data. Symbols represent mean and error bars show s.d. The arrow indicates start of treatment. (B) 
Longitudinal analysis using a linear mixed model applied to time points with treatment effect (days 0 to 10) revealed that ganetespib and 177Lu-octreotate 
synergised to reduce tumour volume. Dashed lines represent individual mice tumours, straight thicker lines represent mean linear regressions for each 
treatment group and the dashed black straight line represents predicted linear regression of an additive effect. (C) The GOT1 xenograft model had a 
morphology consistent with a neuroendocrine tumour, including strong expression of neuroendocrine protein markers. The tumours also stained 
strongly for SSTR2 and Hsp90α/β. CgA, chromogranin A; H&E, haematoxylin and eosin stain; Hsp90, heat shock protein 90; SSTR2, somatostatin receptor 
subtype 2.
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Hsp90 was found to be highly upregulated in tumour cells 
relative to the surrounding tumour stroma (Fig. 4A). The 
Hsp90 expression also varied between tumours, but no 
differences in expression levels were found by comparing 
tumour sites (Fig. 4B). Since a correlation has been found 
between high Hsp90 expression and a poor prognosis in 
other cancer types (Kang et  al. 2010, Wang et  al. 2013, 
Dimas et al. 2018), we investigated whether this was the 
case also for SINETs. We did not find any relationship 
between Hsp90α/β expression and overall survival in 
our cohort, even when we stratified by tumour location 
(Fig. 4C). Since we found that Hsp90 inhibition sensitised 
cancer cells to radiation, we also investigated whether 
innate variations in Hsp90 protein levels could be used 
to predict treatment benefit from 177Lu-octreotate. Among 
investigated tumours, we identified 43 patients that had 
gone through 177Lu-octreotate therapy and retrospectively 
investigated the association between Hsp90α/β expression 
Figure 3
Hsp90i ganetespib synergises with external radiation to reduce the viability of patient-derived tumour cells. (A) Cells from eight patient tumours were 
treated with different doses of ganetespib, external radiation or both in combination. Each symbol represent patient-derived tumour cells from a 
specified patient, bars represent mean of all patient-derived tumour cells and error bars denote standard deviation. (B) The measured synergy effect for 
each patient tumour sample showed that all tumours tended towards synergy. PDTC-LN/PDTC-Liver, patient-derived tumour cells from lymph node 
metastases/liver metastases.
Figure 4
Expression of Hsp90 in SINETs and its relation 
with patient survival. (A) Most SINETs had higher 
expression of Hsp90 in the tumour cells 
compared to the surrounding tumour stroma. (B) 
The expression level of Hsp90 was scored ‘1’ or ‘2’ 
based on staining intensity and showed no 
significant difference in distribution between 
tumour sites. (C) Kaplan–Meier survival analysis of 
a SINET cohort with 312 patients showed no 
association between Hsp90 expression in the 
patient tumour and patient survival. (D) In a 
cohort of 43 SINET patients treated with 
177Lu-octreotate, no association was found 
between Hsp90 expression and patient survival.
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and overall survival after 177Lu-octreotate-treatment for 
these patients. In this cohort, no association between 
Hsp90α/β expression and patient survival was found 
(P = 0.91; Fig. 4D).
Discussion
177Lu-octreotate therapy is a promising treatment modality 
for patients with neuroendocrine tumours. The tumour-
killing efficacy of 177Lu-octreotate therapy is however 
limited and needs to be improved. In this article we 
found that the 177Lu-octreotate therapy can be enhanced 
by inhibiting the heat shock response of tumour cells. 
Hsp90 inhibition as a way of increasing the effect of 
177Lu-octreotate was identified by means of a large-scale 
screening for inhibitors that synergise with radiation in 
SINET cells. By performing a class analysis on all inhibitors 
in the screening, we found that Hsp90 inhibitors were 
overrepresented among inhibitors that synergised with 
radiation in the GOT1 cell line. We also observed that 
Hsp90 inhibitor ganetespib improved 177Lu-octreotate 
therapy synergistically in vivo and that the potentiation 
of radiation-induced tumour-killing persisted ex vivo in 
SINET patient-derived tumour cells.
Hsp90 is a protein-folding chaperone belonging 
to the group of heat shock proteins that assist in 
correct folding of proteins and prevention of faulty 
protein aggregation. When subjected to stress, cells 
upregulate expression of Hsp90 to aid in maintaining 
cellular homeostasis by preventing harmful protein-
protein interactions (Whitesell & Lindquist 2005). The 
Hsp90 chaperone can function both as a potentiator of 
phenotypic manifestations by assisting oncoproteins and 
as a capacitator by allowing tumours to tolerate external 
stress, and also alterations within the cell itself (Karras et al. 
2017). Thus, it is perhaps not surprising to find expression 
of heat shock proteins upregulated in several types of 
human cancers, both solid and haematological (Yufu 
et al. 1992, Chant et al. 1995, Ralhan & Kaur 1995, Conroy 
et al. 1998). Here, for the first time we have shown that 
Hsp90 expression is higher in SINETs relative to tumour 
stroma. Inhibition of Hsp90 has previously been shown to 
sensitise tumour cells to ionising radiation in other types 
of cancer. Hsp90 is involved in a wide range of cellular 
processes and studies in yeast have identified more than 
600 putative Hsp90 substrates (Zhao et al. 2005). Finding 
the mechanism of Hsp90i radiosensitisation is therefore 
a complex task. Proteomic analysis has however shown 
that Hsp90 inhibition predominantly targets kinases and 
components of the DNA damage response (Sharma et al. 
2012) and in particular inhibition of the DNA damage 
repair has been reported in several other studies, mainly in 
the context of delayed or reduced clearance of irradiation-
induced γH2AX foci after Hsp90i treatment (Dote et  al. 
2006, Stingl et  al. 2010, Djuzenova et  al. 2012, Gandhi 
et al. 2013). Authors have attributed this to the two major 
DNA double-strand repair mechanisms: homologous 
recombination repair and non-homologous end joining. 
As mentioned above, kinases are also sensitive to Hsp90 
inhibition, and several kinases that can explain increased 
sensitivity to radiation are reportedly affected by Hsp90i, 
including but not limited to EGFR and ERBB2 (Bisht et al. 
2003, Russell et al. 2003). In addition, inhibition of the 
G2/M checkpoint leading to premature entry or G2/M 
checkpoint arrest have been suggested mechanisms (Bull 
et al. 2004, Dote et al. 2006, Zaidi et al. 2012, Wang et al. 
2016) and it has been speculated that combining Hsp90i 
and radiation can have beneficial immunogenic anti-
tumour effects (Lauber et al. 2015). Ganetespib (STA-9090) 
is a non-geldanamycin, second-generation Hsp90 inhibitor 
that binds to the ATP-binding pocket of the amino (N) 
domain and thereby prevents ATP hydrolysis and therefore 
chaperone function. Ganetespib has shown effect, albeit 
overall limited, as a monotherapy or in combination with 
other therapies, in several solid tumour diseases (Goldman 
et al. 2013, Socinski et al. 2013, Ramalingam et al. 2015, 
Jhaveri et al. 2017, Subramaniam et al. 2018). These trials 
have also demonstrated that ganetespib, in contrast to 
first-generation Hsp90 inhibitors, has improved solubility 
and reduced risk of cardiac, ocular and liver toxicities. 
While Hsp90i to our knowledge has never been studied 
in the context of 177Lu-octreotate therapy, ganetespib 
combined with radiation has shown promising results 
in several preclinical studies (He et  al. 2014, Liu et  al. 
2015, Wang et  al. 2016), providing support to our 
hypothesis that ganetespib radiosensitise neuroendocrine 
tumour cells.
Functional interactions between therapies are often 
classified into three types: additive (without interaction), 
antagonistic (a response that is less than additive) or 
synergistic (a response that is more than additive). 
When combining treatments, it is advantageous to 
achieve a synergistic interaction, as this could increase 
the therapeutic index while reducing toxicity (Fitzgerald 
et  al. 2006). This is, however, complicated by the fact 
that synergistic pairs are rare (4‒10%) (Borisy et  al. 
2003, Zhang et al. 2007, Cokol et al. 2014), which could 
explain why previous combination studies that has tried 
to improve the 177Lu-octreotate through combination 
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therapy have not reported synergistic interactions. Here, 
we performed a comprehensive screening to identify 
inhibitors that synergised with radiation in GOT1 and 
P-STS. In our screening, 2‒3% of the inhibitors showed 
synergistic interactions with radiation and among those 
only the class of Hsp90 inhibitors were significantly 
overrepresented. Inhibitors that synergised with radiation 
represented a diversity of pharmacological principles 
and differed substantially between GOT1 and P-STS. In 
particular, Hsp90i, which was highly overrepresented 
in GOT1, did not show any significant synergy effect in 
P-STS. The fact that Hsp90i showed significant synergy 
with radiation and 177Lu-octreotate in the GOT1 cell line 
and the patient-derived tumour cells, but not in the P-STS 
cell line could be due to several reasons linked to inherent 
features of this cell line. First, P-STS is not necessarily a 
good representative of metastatic well-differentiated 
SINET disease. In fact, P-STS was established from the 
primary tumour of a grade 3 poorly differentiated 
neuroendocrine carcinoma (Pfragner et  al. 2009). GOT1 
and ex vivo cultures were unlike P-STS established from 
metastatic grade 1 or 2 well-differentiated neuroendocrine 
tumours. While likely sharing the same cell of origin, 
neuroendocrine carcinomas and neuroendocrine tumours 
differ in several aspects. In terms of genomic background, 
grade 3 carcinomas frequently harbour TP53 mutations, 
which are very rarely found in grade 1 and 2 tumours. 
TP53 mutations have been shown to alter tumour cell 
biology and lead to a worse patient prognosis for patients 
with neuroendocrine tumours (Sorbye et  al. 2013). We 
have previously found that P-STS harbour such a TP53 
mutation (Hofving et  al. 2018). Patients with poorly 
differentiated neuroendocrine carcinomas have a worse 
prognosis, and differ substantially to well-differentiated 
neuroendocrine tumours in which treatment strategies 
that are commonly applied. For example, 177Lu-octreotate 
is not approved for the treatment of poorly differentiated 
neuroendocrine carcinomas, and its efficacy is yet to be 
proven for these tumours (Strosberg et al. 2010). Secondly, 
P-STS harbour several mutations that are atypical for 
well-differentiated neuroendocrine tumours and that can 
influence the radiosensitivity of the cell line, including 
mutations in BRCA1 and BRCA2 (Hofving et  al. 2018). 
BRCA1 and BRCA2 are essential in DNA double-strand 
repair and these mutations are not normally observed in 
SINETs. One of the most commonly described mechanism 
of HSP90i radiosensitisation is in fact inhibition of DNA 
double-strand repair (Camphausen & Tofilon 2007). It 
has been suggested that both BRCA1 and BRCA2 are key 
proteins in the inhibition of DNA double-strand repair 
by Hsp90 inhibitors (Noguchi et al. 2006, Stecklein et al. 
2012). Thus not only may these aberrant mutations 
explain the increased radiosensitivity of P-STS cells, but it 
is also possible that we do not observe a synergistic effect 
of HSP90i with radiation in P-STS due to the DNA double-
strand repair already being impaired.
In conclusion, we have described a novel combination 
therapy to improve the clinically available 177Lu-octreotate 
therapy for treatment of neuroendocrine tumours. In 
a synergistic manner, the Hsp90 inhibitor ganetespib 
improved 177Lu-octreotate efficacy in the GOT1 cell line 
and xenograft model. The radiosensitising effect was also 
observed in patient-derived tumour cells. We propose that 
the combination of Hsp90i and 177Lu-octreotate should be 
evaluated in a clinical setting.
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